MyoTherix

MyoTherix is involved in R&D and it focuses its research on anti-inflammatory and anti-osteoporosis. The company's lead clinical researchclinical research program focuses on targeting the P2X7 pathway to enhance muscle function and bone health and potentially lower the side effects from the use of steroid. The pre-clinical research program of MyoTherix focuses on enhancing cardiac and skeletal muscle function, lowering inflammation, and aiding new muscle regeneration.

MyoTherix, Inc. is a clinical stage, biopharmaceutical company that focuses on the development of innovative therapies for patients who are suffering from Duchenne muscular dystrophy and other muscular disorders.

MyoTherix is involved in R&D and it focuses its research on anti-inflammatory and anti-osteoporosis. The company's lead clinical research program focuses on targeting the P2X7 pathway to enhance muscle function and bone health and potentially lower the side effects from the use of steroid. The pre-clinical research program of MyoTherix focuses on enhancing cardiac and skeletal muscle function, lowering inflammation, and aiding new muscle regeneration.

MyoTherix works with the team at CureDuchenne in the bid to developing new approaches to the treatment of chronic and devastating disease.